of decline across cancer sites. I analyze the effect that pharmaceutical innovation had on premature cancer mortality in … Canada during the period 2000-2011, by investigating whether the cancer sites that experienced more pharmaceutical innovation … that pharmaceutical innovation during the period 1985-1996 reduced the number of years of potential life lost to cancer …

This paper provides evidence that risk aversion leads pharmaceutical firms to underinvest in radical innovation. We …

We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …

Rewarding inventors with inefficient monopoly power has long been regarded as the price of encouraging innovation …, while simultaneously encouraging dynamic investments in innovation. As a result of this feature, the public provision of … at least $2.8 billion of annual value from extra innovation. These two components alone cover 87% of the social cost of …

stage pharmaceutical innovation? We explore this question using novel data sources and an empirical framework that models … implications of our results for long-run welfare, policy, and innovation …

I examine the impact of pharmaceutical innovation, as measured by the vintage (world launch year) of prescription drugs …

This paper presents an econometric analysis of the effect of changes in the quantity and type of pharmaceuticals …